MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Cash and Cash Equivalents 2011-2026 | NVTA
Annual Cash and Cash Equivalents Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 257 M | 923 M | 131 M | 151 M | 112 M | 12.1 M | 66.8 M | 73.2 M | 107 M | 43.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 923 M | 12.1 M | 188 M |
Quarterly Cash and Cash Equivalents Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 158 M | 223 M | 161 M | 257 M | 217 M | 304 M | 325 M | 923 M | 922 M | 1.11 B | 194 M | 131 M | 125 M | 125 M | 125 M | 151 M | 151 M | 151 M | 151 M | 112 M | 112 M | 112 M | 112 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 107 M | 107 M | 107 M | 107 M | 43.1 M | - | - | - | 21.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 B | 12.1 M | 182 M |
Cash and Cash Equivalents of other stocks in the Diagnostics research industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
19.1 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.48 B | $ 116.92 | 2.67 % | $ 35.5 B |  USA |
 |
Aspira Women's Health
AWH
|
1.76 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
12.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
2.99 M | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Chembio Diagnostics
CEMI
|
18.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
52.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
36.7 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
65.4 M | $ 17.92 | 1.41 % | $ 955 M | USA |
 |
Exact Sciences Corporation
EXAS
|
956 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
59.4 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
1.9 B | $ 16.24 | 0.93 % | $ 175 M |  China |
 |
Co-Diagnostics
CODX
|
11.9 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Heska Corporation
HSKA
|
157 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
2.5 M | $ 1.98 | -0.63 % | $ 8.76 M | USA |
 |
Illumina
ILMN
|
1.13 B | $ 128.0 | 1.23 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
34.9 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
120 M | $ 25.19 | 1.45 % | $ 700 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.66 B | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11.7 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
176 M | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
532 M | $ 274.72 | 2.06 % | $ 22.9 B | USA |
 |
Charles River Laboratories International
CRL
|
214 M | $ 175.07 | 3.26 % | $ 8.68 B | USA |
 |
Medpace Holdings
MEDP
|
497 M | $ 520.65 | 2.39 % | $ 15 B | USA |
 |
Danaher Corporation
DHR
|
4.62 B | $ 196.19 | 2.71 % | $ 140 B | USA |
 |
Motus GI Holdings
MOTS
|
4.96 M | - | -34.28 % | $ 263 K |  Israel |
 |
Myriad Genetics
MYGN
|
150 M | $ 4.77 | 0.63 % | $ 442 M | USA |
 |
Neogen Corporation
NEOG
|
129 M | $ 10.34 | 3.61 % | $ 2.24 B | USA |
 |
National Research Corporation
NRC
|
4.14 M | $ 17.26 | 1.29 % | $ 386 M | USA |
 |
Natera
NTRA
|
466 M | $ 210.83 | 0.75 % | $ 20.7 B | USA |
 |
Organovo Holdings
ONVO
|
11.3 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
1.31 M | - | -16.95 % | $ 1.54 M | USA |
 |
Fulgent Genetics
FLGT
|
55.1 M | $ 15.83 | -0.5 % | $ 479 M | USA |
 |
Pacific Biosciences of California
PACB
|
63.7 M | $ 1.47 | 2.08 % | $ 441 M | USA |
 |
Guardant Health
GH
|
378 M | $ 92.84 | -0.49 % | $ 11.6 B | USA |
 |
PerkinElmer
PKI
|
920 M | - | -0.91 % | $ 14.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
598 M | - | - | $ 10.6 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
1.96 M | - | -1.84 % | $ 15.3 M | USA |
 |
Personalis
PSNL
|
91.4 M | $ 6.33 | 2.59 % | $ 375 M | USA |
 |
Anixa Biosciences
ANIX
|
1.24 M | $ 2.73 | 1.49 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
2.4 M | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
Quotient Limited
QTNT
|
45.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
752 M | $ 106.54 | -0.58 % | $ 8.79 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
7.7 M | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
166 M | $ 116.94 | 1.19 % | $ 5.47 B | USA |